NCT01359956 2023-04-11
SICOG 0109
National Cancer Institute, Naples
Phase 3 Completed
Clinical Trials
12 trialsNCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT01943422 2018-04-03
12-107
University of Pittsburgh
Phase 1 Completed
NCT00204529 2017-05-03
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
University Hospital Tuebingen
Phase 3 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT00723710 2015-08-26
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Merck Sharp & Dohme LLC
Completed
NCT01462773 2015-01-13
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed